From JPMA From the "Pharmaceutical Association of Japan Press Conference
1: Creating an environment to promote innovation
Since announcing the progress of our policy recommendations in January 2019, we have continued our conversations with the government through public-private dialogue and advisory meetings. As a result, we believe that our requests have been incorporated into the policy and that measures for further industry-academia-government collaboration can be expected in the Kotta Policy 2019 and the next draft of the Health and Medical Care Strategy. We have also started to consider joint research with relevant stakeholders. We are already working on a highly concrete research plan and hope to begin the implementation phase in 2020.
In addition, the Pharmaceutical Manufacturers Association of Japan (PMAJ) has been participating in the study of the "Action Plan for Promoting Genomic Medicine," which will be launched in 2019. As a result, the first version of the action plan has been prepared. It is necessary to discuss more detailed parts of the plan in the future, and the Pharmaceutical Manufacturers Association will continue to actively participate in the discussions.
Regarding the R&D taxation system, several requests from the industry side were reflected in the April 2019 revision. We will actively utilize the expanded tax system and communicate with the government to ensure that the time-limited measures are extended to 2021.
Japan Pharmaceutical Manufacturers Association Chairman Joji Nakayama
2: Appropriate evaluation of innovation
As part of our efforts to promote the proper use of pharmaceuticals, we have been co-hosting a seminar on drug resistance (AMR) with the Japan Medical Association, a public interest incorporated association, and working with the Council on the Proper Use of Drugs to create public awareness materials on polypharmacy. In the future, we will further strengthen and promote initiatives for proper use of drugs, such as holding media forums related to polypharmacy.
With regard to NHI drug price reform, we have requested that the NHI system be revised to appropriately reflect the medical value of pharmaceuticals, such as by improving the additional payment for new drug creation, etc., in preparation for the FY2020 NHI drug price reform. We will continue to study the "reorganization of the evaluation system for new drugs" and "establishment of an evaluation system that is easy for the public to understand" for the FY2022 NHI drug price reform. In addition, we will also work on "organizing the thinking behind the consideration of an all-generation social security system.
(From the Pharmaceutical Manufacturers Association of Japan Newsletter, March 2020, No. 196, Top News)
Japan Pharmaceutical Manufacturers Association (Pharmaceutical Manufacturers Association of Japan) Japan Pharmaceutical Manufacturers Association (JPMA)
The Pharmaceutical Manufacturers Association of Japan (PMAJ), founded in 1968, is an association of R&D-oriented pharmaceutical companies that aim to contribute to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
The organization is dedicated to promoting a deeper understanding of pharmaceuticals and providing policy recommendations for the sound development of the pharmaceutical industry, with the aim of realizing patient-participatory medicine.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Manufacturers Association of Japan (PAPJ) is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association